ASX RELEASE 01 February, 2022

The Company Announcements Office
Australian Securities Exchange
via electronic lodgement

Paradigm Biopharmaceuticals Limited ACN 169 346 963 (ASX: PAR)
Cleansing Notice under section 708A of the Corporations Act 2001 (Cth)

On 25 January 2022, Paradigm Biopharmaceuticals Limited ACN 169 346 963 (**Company**) issued 375,000 fully paid ordinary shares in the Company at an issue price of $1.89 per share pursuant to the Company's Employee Share Plan (ESP).

The Company gives this notice under section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (**Corporations Act**). The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, the Company has complied with:

- the provision of Chapter 2M of the Corporations Act as they apply to the Company; and
- section 674 of the Corporations Act.

As at the date of this notice, there is no excluded information for the purposes of section 708A(7) and section 708A(8) of the Corporations Act.

Yours faithfully



Justin Cahill
CFO Paradigm Biopharmaceuticals Limited
Acting Company Secretary on 01 February 2022

This announcement was authorised for release by Paradigm Board of Directors.

FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email : investorrelations@paradigmbiopharma.com